J B Chemicals and Pharmaceuticals Ltd

J B Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live

eClerx Services Ltd, Bajaj Finserv Ltd, Marico Ltd, Force Motors Ltd are among the other stocks to see a surge in volumes on BSE today, 28 January 2026.J B Chemicals & Pharmaceuticals Ltd recorded volume of 2.11 lakh shares by 10:46 IST on BSE, a 62.37 times surge over two-week average daily volume of 3382 shares. The stock lost 1.29% to Rs.1,857.00. Volumes stood at 2097 shares in the last session.eClerx Services Ltd registered volume of 2.11 lakh shares by 10:46 IST on BSE, a 34.71 fold spurt over two-week average daily volume of 6080 shares. The stock slipped 0.07% to Rs.4,401.80. Volumes stood at 2896 shares in the last session.Bajaj Finserv Ltd notched up volume of 20.44 lakh shares by 10:46 IST on BSE, a 22.17 fold spurt over two-week average daily volume of 92220 shares. The stock rose 0.82% to Rs.1,931.40. Volumes stood at 63797 shares in the last session.Marico Ltd witnessed volume of 4.93 lakh shares by 10:46 IST on BSE, a 15.15 times surge over two-week average daily volume of 32546 shares. The stock dropped 3.03% to Rs.723.30. Volumes stood at 36396 shares in the last session.Force Motors Ltd registered volume of 87933 shares by 10:46 IST on BSE, a 10.69 fold spurt over two-week average daily volume of 8227 shares. The stock rose 0.25% to Rs.18,845.00. Volumes stood at 14290 shares in the last session.Powered by Capital Market - Live

J B Chemicals & Pharmaceuticals has allotted 37,84,100 equity shares under ESOS on 21 January 2026. Consequently, the issued, subscribed and paid-up capital has increased from 15,66,50,956 equity shares of Re. 1 each to 16,04,35,056 equity shares of Re. 1 each. Powered by Capital Market - Live

Profit before tax (PBT) stood at Rs 266.87 crore in Q3 FY26, up 22.42% from Rs 217.99 crore reported in the corresponding quarter last year. In Q3 FY26, operating EBITDA stood at Rs 305 crore, up 12.96%, compared with Rs 270 crore posted in the same quarter last year. Operating EBITDA margin stood at 28.7% in Q3 FY26 as against 28.1% in Q3 FY25. Nikhil Chopra, CEO and whole-time director of JB Pharma, stated, 'JB Pharma's domestic formulations business once again outperformed the Indian pharmaceutical market, driven by broad-based momentum across key chronic therapies and continued strength in our flagship brands. On the international front, while the CDMO business continued its positive momentum, the international formulations business also recorded strong growth in several key markets. Our focus on cost optimization, favorable product mix, and operational efficiencies led to improved operating margins for Q3 FY26 as well as for 9M FY26. With a strong balance sheet, net cash position, and sustained cash flow generation, we remain confident in our ability to deliver profitable growth. As we move forward, our priorities remain centered on strengthening flagship brand franchises, accelerating growth in chronic therapies, scaling our CDMO businesses, and building a resilient, agile, and future-ready organization.' JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radiodiagnostics, APIs, and intermediates.Powered by Capital Market - Live

J B Chemicals & Pharmaceuticals Ltd is up for a third straight session in a row. The stock is quoting at Rs 1925.9, up 1.15% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.67% on the day, quoting at 25522.15. The Sensex is at 83010.66, down 0.67%. J B Chemicals & Pharmaceuticals Ltd has risen around 6.57% in last one month. Meanwhile, Nifty Pharma index of which J B Chemicals & Pharmaceuticals Ltd is a constituent, has risen around 3.29% in last one month and is currently quoting at 22217.05, down 0.2% on the day. The volume in the stock stood at 1.11 lakh shares today, compared to the daily average of 1.71 lakh shares in last one month.The PE of the stock is 42.28 based on TTM earnings ending September 25.Powered by Capital Market - Live

Net profit of J B Chemicals & Pharmaceuticals rose 21.79% to Rs 197.89 crore in the quarter ended December 2025 as against Rs 162.49 crore during the previous quarter ended December 2024. Sales rose 10.51% to Rs 1064.72 crore in the quarter ended December 2025 as against Rs 963.49 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1064.72963.49 11 OPM %27.7826.42 - PBDT312.22259.93 20 PBT266.87217.99 22 NP197.89162.49 22 Powered by Capital Market - Live

J B Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 16 January 2026.Powered by Capital Market - Live

J B Chemicals & Pharmaceuticals has allotted 2,500 equity shares under ESOS on 06 December 2025. Consequently, the issued, subscribed and paid-up capital has increased from 15,66,48,456 equity shares of Re. 1 each to 15,66,50,956 equity shares of Re. 1 each. Powered by Capital Market - Live

J B Chemicals & Pharmaceuticals Ltd is down for a fifth straight session today. The stock is quoting at Rs 1731, down 1% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.29% on the day, quoting at 26115.75. The Sensex is at 85365.62, down 0.31%.J B Chemicals & Pharmaceuticals Ltd has added around 1.3% in last one month.Meanwhile, Nifty Pharma index of which J B Chemicals & Pharmaceuticals Ltd is a constituent, has increased around 0.76% in last one month and is currently quoting at 22687.55, down 0.15% on the day. The volume in the stock stood at 1.69 lakh shares today, compared to the daily average of 2.14 lakh shares in last one month.The PE of the stock is 38.76 based on TTM earnings ending September 25.Powered by Capital Market - Live

Profit before tax (PBT) stood at Rs 279.15 crore in Q2 FY26, up 18% from Rs 236.53 crore reported in the corresponding quarter last year. In Q2 FY26, operating EBITDA stood at Rs 319 crore, up 12%, compared with Rs 285 crore posted in the same quarter last year. Operating EBITDA margin stood at 29.4% in Q2 FY26 as against 28.4% in Q2 FY25. Nikhil Chopra, CEO and whole-time director of JB Pharma, stated, 'The company's domestic business continued to outperform the market, with all major brands delivering robust growth. Our focus on driving steady volume growth across key brands'including recently acquired portfolios'continues to yield good results. On the international front, momentum in our CDMO business has returned, supported by a solid order book that positions us for further growth in the second half of the year. Over the years, JB has consistently delivered strong revenue and margin performance. We are confident in sustaining this positive momentum as we progress toward our operational and strategic goals for the current year and beyond. As we chart the path ahead, our focus remains on building a progressive, agile, and future-ready organization.' JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radiodiagnostics, APIs, and intermediates. Shares of JB Chemicals & Pharmaceuticals shed 0.41% to Rs 1,819.25 on the BSE.Powered by Capital Market - Live